Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial.
Katja Kovacic, Keri Hainsworth, Manu Sood...
https://pubmed.ncbi.nlm.nih.gov/28826627/Actively Recruiting
Led by Medical College of Wisconsin · Updated on 2026-02-13
120
Participants Needed
1
Research Sites
26 weeks
Total Duration
This research aims to better understand disorders of gut-brain interaction DGBI in female children aged 11 to 18 who experience symptoms like cyclic vomiting and functional dyspepsia along with signs of autonomic nervous system ANS imbalance. These conditions often include disabling symptoms such as sleep disturbances, fatigue, anxiety, palpitations, and dizziness. The study focuses on the brain-gut mechanisms behind these symptoms and evaluates treatments targeting the ANS regulation through novel methods. Participants will receive personalized percutaneous electrical nerve field stimulation PENFS therapy applied to the external ear for six weeks. Some will also receive adjunctive gut-directed hypnotherapy through audio recordings. The study evaluates real-time ANS regulation using a new tracking software and adjusts neurostimulation parameters based on individual sensory thresholds. A subset of participants will undergo advanced MRI to assess gastric function before and after therapy. Throughout the study, participants will be monitored weekly for autonomic nervous system activity and symptom changes using patient-reported outcomes and gastrointestinal symptom severity assessments. Researchers will measure vagal efficiency and symptom response to personalize treatment. The trial includes a six-week treatment period with follow-up evaluations to assess therapy effects. Safety and symptom reporting will be carefully observed during the study period.
CONDITIONS
Autonomic Reactivity and Personalized Neurostimulation
E
Elaina Schueler, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical College of Wisconsin
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PENFS device therapy | PENFS plus gut-directed hypnotherapy |
|---|---|---|
| What it is | Percutaneous electrical nerve field stimulation (PENFS) uses a device applied to the external ear to deliver mild electrical impulses once weekly over several weeks. This device is being investigated for symptom relief in functional gastrointestinal disorders and dysautonomia. | This approach combines PENFS device therapy with structured gut-directed hypnotherapy delivered through audio recordings, aiming to address both autonomic and gastrointestinal symptoms. |
| Role in trial | Serves as the investigational device-only arm for comparison in this randomized therapeutic study. | Assesses whether combining hypnotherapy with PENFS enhances symptom improvement beyond PENFS alone. |
| Primary use | Explored for symptom management in adolescents with functional GI disorders such as cyclic vomiting syndrome or functional dyspepsia and symptoms of autonomic dysfunction. | Designed to determine if adding gut-directed hypnotherapy to nerve field stimulation improves gastrointestinal and autonomic symptoms beyond device therapy alone. |
| How it is given or performed | The nerve field stimulator is applied to the external ear once weekly for several consecutive weeks. | Participants receive PENFS device therapy as above, plus complete guided hypnotherapy sessions via audio, targeting gut function improvement. |
| Evidence status | Randomized trials and observational studies suggest PENFS can improve symptoms and vagal function in adolescents with functional abdominal pain and nausea, though evidence remains limited for dysautonomia in the FGID population. | While PENFS has some supporting evidence, the combined effectiveness of PENFS with hypnotherapy in this adolescent population is not established in published trials and is the focus of investigation. |
| Important limitations | Previous PENFS trials in adolescents with GI disorders are small and short-term, with limited data on safety and sustained efficacy, and little is known about effects in the subgroup with prominent dysautonomia. | No published studies have directly evaluated the PENFS and hypnotherapy combination in this group, so longer-term safety and benefit are unknown. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 weeks
Participants receive percutaneous electrical nerve field stimulation (PENFS) therapy personalized weekly based on autonomic nervous system assessments. Some participants also receive adjunctive gut-directed hypnotherapy via audio recordings.
Weekly visits for up to 6 weeks
Duration - Short-term period after 6 weeks of treatment
Participants continue to have assessments of autonomic nervous system function and symptom response after treatment completion.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Katja Kovacic, Keri Hainsworth, Manu Sood...
https://pubmed.ncbi.nlm.nih.gov/28826627/Katja Kovacic, Jacek Kolacz, Gregory F Lewis...
https://pubmed.ncbi.nlm.nih.gov/32732620/Jacek Kolacz, Katja Kovacic, Linh Dang...
https://pubmed.ncbi.nlm.nih.gov/36716443/Jacek Kolacz, Olivia K Roath, Gregory F Lewis...
https://pubmed.ncbi.nlm.nih.gov/39888101/A Menys, D Keszthelyi, H Fitzke...
https://pubmed.ncbi.nlm.nih.gov/28568908/T Venkatesan, T Prieto, A Barboi...
https://pubmed.ncbi.nlm.nih.gov/20667005/Roberta Sclocco, Ronald G Garcia, Norman W Kettner...
https://pubmed.ncbi.nlm.nih.gov/30803865/Gregory F Lewis, Senta A Furman, Martha F McCool...
https://pubmed.ncbi.nlm.nih.gov/22138367/G Holtmann, H Goebell, F Jockenhoevel...
https://pubmed.ncbi.nlm.nih.gov/9616311/Medical College of Wisconsin
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor